Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30200709 | 1.00 | GRM5 (0.46) | GRM5MAP2K1CYP11B1CYP11B2VNN1 | |
| SCHEMBL15190392 | 0.95 | GRM5 (0.44) | GRM5MAP2K1CYP11B1CYP11B2VNN1 | |
| SCHEMBL409948 | 0.88 | MEN1 (0.50) | MAP2K1CYP11B1CYP11B2ALDH1A1SMN1; SMN2 | |
| SCHEMBL11520744 | 0.84 | CA12 (0.46) | MAP2K1CYP11B1CYP11B2ALDH1A1HPGD | |
| SCHEMBL1476889 | 0.84 | GRM5 (0.46) | GRM5MAP2K1CYP11B1CYP11B2VNN1 | |
| SCHEMBL20564444 | 0.83 | ALDH1A1 (0.42) | MAP2K1ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL536199 | 0.83 | MEN1 (0.46) | MAP2K1CYP11B1CYP11B2TRPA1ALDH1A1 | |
| SCHEMBL20944310 | 0.83 | TSHR (0.46) | CYP11B1CYP11B2ALDH1A1TSHRHSD17B10 | |
| SCHEMBL30728619 | 0.82 | HPGD (0.42) | GRM5CYP11B1CYP11B2ALDH1A1HPGD | |
| SCHEMBL29170780 | 0.82 | HPGD (0.42) | GRM5CYP11B1CYP11B2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025098515-A1 | HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2025-02-06 | — | — | US | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | RIBOSCIENCE LLC (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-4249070-A2 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3466929-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | MILLENNIUM PHARM INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-2118055-A1 | ANTIPARASITIC AGENTS | Pfizer Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-7608604-B2 | Antiparasitic agents | PFIZER LIMITED (GB) | 2009-10-27 | — | — | US | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | PFIZER LIMITED (UK) | 2008-08-14 | — | — | US | disclosed |
| WO-2008096231-A1 | ANTIPARASITIC AGENTS | PFIZER LIMITED (GB) | 2008-08-14 | — | — | WO | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2001030745-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | HRH4, HRH3, HRH2 | GRM5 1686/4885MAP2K1 4503/4885CYP11B1 954/4885 |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GRM5 3566/4885MAP2K1 582/4885CYP11B1 1113/4885 |
| US-20250041319-A1 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, SMPD1 | GRM5 2382/4885MAP2K1 2361/4885CYP11B1 119/4885 |
| US-12029744-B2 | Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors | ENPP1, ENPP3, SMPD1 | GRM5 2383/4885MAP2K1 2402/4885CYP11B1 127/4885 |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | GRM5 787/4885MAP2K1 3926/4885CYP11B1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.